select a format

Single User License
USD 2000 INR 128240
Site License
USD 4000 INR 256480
Corporate User License
USD 6000 INR 384720

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2015

Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2015


  • Products Id :- GMDHC7235IDB
  • |
  • Pages: 83
  • |
  • October 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Chagas Disease (American Trypanosomiasis)-Pipeline Review, H2 2015', provides an overview of the Chagas Disease (American Trypanosomiasis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chagas Disease (American Trypanosomiasis) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chagas Disease (American Trypanosomiasis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chagas Disease (American Trypanosomiasis) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Chagas Disease (American Trypanosomiasis) Overview 9

Therapeutics Development 10

Pipeline Products for Chagas Disease (American Trypanosomiasis)-Overview 10

Pipeline Products for Chagas Disease (American Trypanosomiasis)-Comparative Analysis 11

Chagas Disease (American Trypanosomiasis)-Therapeutics under Development by Companies 12

Chagas Disease (American Trypanosomiasis)-Therapeutics under Investigation by Universities/Institutes 13

Chagas Disease (American Trypanosomiasis)-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Chagas Disease (American Trypanosomiasis)-Products under Development by Companies 18

Chagas Disease (American Trypanosomiasis)-Products under Investigation by Universities/Institutes 19

Chagas Disease (American Trypanosomiasis)-Companies Involved in Therapeutics Development 21

Anacor Pharmaceuticals, Inc. 21

Eisai Co., Ltd. 22

Grupo Praxis Pharmaceutical SA 23

Merck & Co., Inc. 24

Panacela Labs, Inc. 25

Sanofi 26

SEEK Group 27

Chagas Disease (American Trypanosomiasis)-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

benznidazol-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

chagas disease (bivalent) vaccine-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

chagas disease vaccine-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

chagas disease vaccine-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

chagas disease vaccine-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Cz-007-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Cz-008-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

EPLBS-1246-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

EPLBS-967-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

fexinidazole-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

fosravuconazole-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

K-777-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

LH-7-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Monoclonal Antibody for Chagas-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

NEU-321-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

posaconazole-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Small Molecule to Inhibit Cruzipain for Chagas Disease-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Small Molecules for Chagas Disease-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules for Chagas Disease-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules for Chagas Disease-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Small Molecules for Chagas Disease-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecules for Chagas Disease-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Small Molecules for Infectious Diseases-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Small Molecules for Infectious Diseases-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Small Molecules for Protozoal Infections-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Small Molecules to Inhibit Proline Racemase for Chagas Disease-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Vaccine for Chagas Disease-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

VNI-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

XELRYX-3-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Chagas Disease (American Trypanosomiasis)-Recent Pipeline Updates 73

Chagas Disease (American Trypanosomiasis)-Dormant Projects 75

Chagas Disease (American Trypanosomiasis)-Discontinued Products 76

Chagas Disease (American Trypanosomiasis)-Product Development Milestones 77

Featured News & Press Releases 77

Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 77

Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 77

May 03, 2013: Funding boost for GSK's open innovation research into diseases affecting the developing world 79

Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 80

Mar 12, 2012: DNDi Receives 2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 80

Appendix 82

Methodology 82

Coverage 82

Secondary Research 82

Primary Research 82

Expert Panel Validation 82

Contact Us 82

Disclaimer 83

List of Tables

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2015 10

Number of Products under Development for Chagas Disease (American Trypanosomiasis)-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 14

Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd...1) 15

Comparative Analysis by Clinical Stage Development, H2 2015 16

Comparative Analysis by Early Stage Development, H2 2015 17

Products under Development by Companies, H2 2015 18

Products under Investigation by Universities/Institutes, H2 2015 19

Products under Investigation by Universities/Institutes, H2 2015 (Contd...1) 20

Chagas Disease (American Trypanosomiasis)-Pipeline by Anacor Pharmaceuticals, Inc., H2 2015 21

Chagas Disease (American Trypanosomiasis)-Pipeline by Eisai Co., Ltd., H2 2015 22

Chagas Disease (American Trypanosomiasis)-Pipeline by Grupo Praxis Pharmaceutical SA, H2 2015 23

Chagas Disease (American Trypanosomiasis)-Pipeline by Merck & Co., Inc., H2 2015 24

Chagas Disease (American Trypanosomiasis)-Pipeline by Panacela Labs, Inc., H2 2015 25

Chagas Disease (American Trypanosomiasis)-Pipeline by Sanofi, H2 2015 26

Chagas Disease (American Trypanosomiasis)-Pipeline by SEEK Group, H2 2015 27

Assessment by Monotherapy Products, H2 2015 28

Number of Products by Stage and Target, H2 2015 30

Number of Products by Stage and Mechanism of Action, H2 2015 32

Number of Products by Stage and Route of Administration, H2 2015 34

Number of Products by Stage and Molecule Type, H2 2015 36

Chagas Disease (American Trypanosomiasis) Therapeutics-Recent Pipeline Updates, H2 2015 73

Chagas Disease (American Trypanosomiasis)-Dormant Projects, H2 2015 75

Chagas Disease (American Trypanosomiasis)-Discontinued Products, H2 2015 76

List of Figures

Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2015 10

Number of Products under Development for Chagas Disease (American Trypanosomiasis)-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Number of Products under Investigation by Universities/Institutes, H2 2015 13

Comparative Analysis by Early Stage Products, H2 2015 17

Assessment by Monotherapy Products, H2 2015 28

Number of Products by Targets, H2 2015 29

Number of Products by Stage and Targets, H2 2015 29

Number of Products by Mechanism of Actions, H2 2015 31

Number of Products by Stage and Mechanism of Actions, H2 2015 31

Number of Products by Routes of Administration, H2 2015 33

Number of Products by Stage and Routes of Administration, H2 2015 33

Number of Products by Molecule Types, H2 2015 35

Number of Products by Stage and Molecule Types, H2 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anacor Pharmaceuticals, Inc.

Eisai Co., Ltd.

Grupo Praxis Pharmaceutical SA

Merck & Co., Inc.

Panacela Labs, Inc.

Sanofi

SEEK Group

Chagas Disease (American Trypanosomiasis) Therapeutic Products under Development, Key Players in Chagas Disease (American Trypanosomiasis) Therapeutics, Chagas Disease (American Trypanosomiasis) Pipeline Overview, Chagas Disease (American Trypanosomiasis) Pipeline, Chagas Disease (American Trypanosomiasis) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com